FDA Clears Subcutaneous Isatuximab for Multiple Myeloma Treatment

The U.S. Food and Drug Administration (FDA) has granted approval for a subcutaneous version of isatuximab-irfc, known as Sarclisa Escena, for all existing multiple myeloma treatments. This new formulation offers an alternative administration method for patients. Clinical trials confirmed its effectiveness is comparable to the intravenous form, providing a more convenient option.